Edgewise completes sevasemten sale to Servier, sharpens cardiovascular focus
The July 10, 2026 closing brings Edgewise $1.55 billion upfront plus up to $1.1 billion in milestones, funding EDG-7500 through potential approval.
Edgewise Therapeutics said on July 13, 2026 that it has completed the previously disclosed sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group governed by a foundation. The deal gives Edgewise $1.55 billion in upfront cash consideration and eligibility for up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.1
The 8-K confirms the transaction closed on July 10, 2026, with Servier Pharmaceuticals LLC and Les Laboratoires Servier acquiring the sevasemten compound and related assets making up Edgewise's muscular dystrophy program, under the same $1.55 billion upfront and up to $1.1 billion milestone structure.1 The company said the terms match those described in its Form 8-K filed June 1, 2026.1
Under the agreement, Servier acquired all rights to sevasemten, including related intellectual property, know-how, key agreements, regulatory filings, and clinical data required to operate the muscular dystrophy business.1 Edgewise employees who primarily supported the muscular dystrophy business received offers to transition to Servier.1
The company said the sale strengthens its balance sheet and sharpens its focus on cardiovascular drug development, with a pipeline now comprising EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003 for an undisclosed target.1
On sevasemten, the pivotal "GRAND CANYON" cohort in Becker muscular dystrophy is fully enrolled with 175 participants, statistically powered at greater than 98% versus placebo, with topline data expected in the fourth quarter of 2026.1
On the cardiovascular pipeline, Edgewise pointed to favorable 12-week results from Part D of its "CIRRUS-HCM" Phase 2 study of EDG-7500 covering safety, cardiac imaging, biomarker, and patient-reported measures in both obstructive and non-obstructive hypertrophic cardiomyopathy patients. Based on that data, the company expects to start a Phase 3 trial in the fourth quarter of 2026.1 A Phase 2 trial of EDG-15400 in heart failure with preserved ejection fraction remains on track to begin as planned.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.